Enriched plasma derivative for enhancement of wound closure and coverage
Patent 4427651 Issued on January 24, 1984. Estimated Expiration Date: 
June 7, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 7, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesTissue adhesive Tissue adhesive Patent #: 4362567 InventorAssigneeApplicationNo. 06/385665 filed on 06/07/1982US Classes:424/46, Powder or dust containing424/45, Organic pressurized fluid424/531, Serum424/532, Platelet514/21, Produced by or extracted from animal tissue514/802, FIBRINOPEPTIDES, BLOOD-COAGULATION FACTORS OR DERIVATIVES530/363, Serum albumin, e.g., BSA, HSA, etc.530/381, Blood coagulation factors and fibrin, e.g., thromboplastin, etc.530/382, Fibrin or fibrin intermediates, e.g., fibrinogen, etc.530/383, Blood coagulation factor VIII, AHF530/384, Blood coagulation factor II or factor II + VII + IX + X, i.e., prothrombin complex or factor530/386, Globulins530/830Plasma; serumExaminersPrimary: Rosen, SamAttorney, Agent or FirmInternational ClassesA61K 35/14 (20060101)A61K 38/00 (20060101) A61K 38/43 (20060101) A61K 38/48 (20060101) A61K 38/36 (20060101) A61L 27/00 (20060101) A61L 24/00 (20060101) A61L 24/10 (20060101) A61L 26/00 (20060101) A61L 27/22 (20060101) A61F 2/00 (20060101) Foreign Application Priority Data1981-06-25 DEAbstractA sprayable preparation for accelerated hemostasis and optimized biochemical control of wound closure contains a powdery mixture of 15 to 60% by weight of thrombin, 5 to 80% by weight of a desiccating and stabilizing agent, viz., albumin, globulin and/or fibrinogen, and 1 to 10% by weight of a fibrinolysis inhibitor. The powdery mixture is suspended in a low-boiling, anhydrous solvent, which is used as a propellant. For effective wound closure and coverage, a spray jet of this suspension is directed onto the wound under evaporation of the solvent so that substantially only the dry, solid powdery mixture reaches the wound. This method of application by spraying is also disclosed.Other References
|
| ||||||||||||||
